301130.SZ
Jilin Province Xidian Pharmaceutical Sci-Tech Dev Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 24.90
+2.68%Oct 26, 2026, 07:51 UTC
Xidian Pharmaceutical reported revenue of RMB 149 million, net profit of RMB 6.4801 million and adjusted net profit of RMB 3.6987 million for the first three quarters of 2026.
Source:Oct 26, 2026, 07:51 UTC
Xidian Pharmaceutical reported third-quarter 2026 revenue of RMB 48.0224 million, down 20.80% year over year, and a net loss of RMB 2.4472 million, compared with net profit of RMB 8.2018 million a year earlier.
Source:Sep 3, 2026, 07:51 UTC
Xidian Pharmaceutical received a drug supplementary application approval notice from China's National Medical Products Administration for potassium chloride granules, approving the transfer of the marketing authorization holder from Suzhou Langke Biotechnology to Xidian.
Source:Aug 25, 2026, 09:05 UTC
Xidian Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders fell 64.21% year-on-year to 8.9272 million yuan, with revenue down 20.95% to 101 million yuan.
Source:Aug 20, 2026, 07:47 UTC
Xidian Pharmaceutical announced that its registration application for Potassium Chloride Granules was accepted by China's National Medical Products Administration (NMPA).
Source: